Fairer way to distribute last-ditch drugs gets real-world trial.
Sara
S
Reardon
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002648:Child; D057176:Compassionate Use Trials / Q000941:ethics / Q000331:legislation & jurisprudence / Q000379:methods*; D018849:Controlled Clinical Trials as Topic / Q000379:methods; D003596:Cytosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D017277:Drug Approval / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000941:ethics / Q000331:legislation & jurisprudence / Q000379:methods*; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy*; D063065:Organophosphonates / Q000627:therapeutic use; D010344:Patient Advocacy; D018579:Patient Selection / Q000941:ethics*; D061108:Social Media / Q000706:statistics & numerical data; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence
D000911:Antibodies, Monoclonal; D063065:Organophosphonates; C556306:daratumumab; C525733:brincidofovir; D003596:Cytosine